Cargando…
Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma
Isocitrate dehydrogenases (IDH1/2) are central molecular markers for glioblastoma. Providing in vitro or in vivo models with mutated IDH1/2 can help prepare facilities to understand the biology of these mutated genes as glioma markers, as well as help, improve therapeutic strategies. In this review,...
Autores principales: | Mehrjardi, Narges Zare, Hänggi, Daniel, Kahlert, Ulf Dietrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680457/ https://www.ncbi.nlm.nih.gov/pubmed/33221817 http://dx.doi.org/10.1038/s41419-020-03196-0 |
Ejemplares similares
-
Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023) -
Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
por: Radoul, Marina, et al.
Publicado: (2021) -
Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019) -
Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023) -
Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)